guidelines for the management of urological cancer - Merseyside ...

More documents

Recommendations

Info

6.54 Recurrent Muscle-Invasive Tumours (Appendix 8) 7. FOLLOW UP AFTER RADICAL TREATMENT 7.1 Invasive Bladder Cancer Treated by Surgery Cystectomy, ileal conduit or neobladder Patients will be reviewed at the cancer centre initially extending to shared care between the cancer centre and the referring local MDT. A six week post surgery visit will be arranged to exclude complications of surgery, assess recovery and inform patients of outcome and diagnosis. (S) Patients will have a physical examination including an assessment of the ileal conduit or diversion, serum haemoglobin and creatinine will be performed as well as acid base estimation in patients with bladder reconstruction.(S) For all patients either a conduitogram or an IVU should be arranged at six weeks. (S) All cystectomy patients should be seen 3 monthly in the first 2 years, then 6 monthly alternating after the first year with the local MDT as requested.(G) Patients should be seen by a specialist nurse practitioner in stoma and reconstruction. (G) 7.2 Invasive Bladder Cancer Treated by Radiotherapy 6 weeks Oncology review (S) 1st post-RT cystoscopy(GA) at 3 months (S) If clear, CT and flexible cystoscopy at 6 months (G) If clear at 6 months, flexible cystoscopy three monthly for 18 months, with CT at 1 year post RT (G) If clear, flexible cystoscopy six monthly for 4 years, then annually for life (G) If residual/recurrent tumour, restage with a low threshold for salvage cystectomy especially for high grade tumour & MDT (S) If CT shows nodes, then consider chemotherapy/palliative radiotherapy & MDT (S) 8. PATIENT AND CARER INFORMATION Patients will be contacted by the local MDT key worker to inform them that their case has been discussed at the SMDT and that they will be seen the following week by the appropriate member of the core team. This process will be co-ordinated centrally by the Specialist Nurses. The Uro-Oncology team will discuss the diagnosis, MDT action plan and care pathway with patients and carers. Patients/carers will receive relevant written information about their diagnosis and treatment plan. Patients with visual and hearing impairment will be offered aids to understand the patient information. Interpreter services are available for patients via the patient advisory liaison office. Patients will be asked if they wish to receive a copy of the permanent consultation record which outlines the information that they have been given. It includes the diagnosis and the treatment plan agreed by the patient at the meeting with the urologist. Patients should be seen by a specialist nurse practitioner in stoma and reconstruction as appropriate. Many aspects of palliative care are also applicable earlier in the course of the illness in conjunction with anti-cancer or other treatment.(Please refer to the Palliative Care section) Page 22 of 44
All patients will be offered clear and comprehensive information in a format which is suitable to their needs and stage of treatment in the cancer journey, this should include: • Nature of the disease • Diagnostic procedures being undertaken • Treatment options available • Likely outcomes of treatment in terms of benefits, risks and side effects • Management of side effects of treatment, and who would be most appropriate to contact for advice • Details of future appointments/contacts • Contact details of clinical nurse specialist/key worker for urological cancers • Contact details of clinical nurse specialist for other individual issues (stoma care/continence advice/sexual issues/body image issues) as appropriate • Cancer information services such as Cancer BACKUP • Where appropriate patients should receive a copy of any medical/clinical communications e.g. from surgeon/GP • Details of MDT • The role and responsibilities of their CNS Hard copies of the information, available within the Merseyside and Cheshire Cancer Network for patients with urological cancer and their carers, can be obtained from the clinical nurse. This information will meet agreed MCCN / National Patient Information Guidelines, as per mapping Access will be made available for all patients/carers to a named nurse whose specialist knowledge is in urological cancers As the concept of the information prescription is introduced, urology patients will be included in the process. Patient satisfaction surveys will be carried out annually and results acted upon. 9. PALLIATIVE CARE Palliative Care is defined by the World Health Organisation (WHO 2002) as: “...the active holistic care of patients with advanced progressive illness. Management of pain and other symptoms and provision of psychological, social and spiritual support is paramount. The goal of palliative care is achievement of the best quality of life for patients and their families. Many aspects of palliative care are also applicable earlier in the course of the illness in conjunction with other treatments” Many patients with advanced incurable bladder cancer will not require referral to specialist palliative care, but will find that their supportive care can be managed by their GP and district nursing team. Patients felt to be in the last 6 – 12 months of life should be included on the GP practice’s Supportive Care Register (also known as a GSF register). This will ensure that the needs of both the patient and their carers are regularly assessed and will promote discussions about Advance Care Planning. An Holistic Needs Assessment should be undertaken to identify the patient’s needs and ensure the care plan meets those needs. Page 23 of 44
Page 1 and 2: GUIDELINES FOR THE MANAGEMENT OF UR
Page 3 and 4: Appendix 1 - SMDT contacts Appendix
Page 5 and 6: 1.2 Definition of Terms Carcinoma i
Page 7 and 8: Patients with haematuria may have a
Page 9 and 10: 4. ASSESSMENT OF IDENTIFIED BLADDER
Page 11 and 12: 5.1 Referral to the SMDT 1. It is t
Page 13 and 14: For patients referred from the loca
Page 15 and 16: 6.1 Page 15 of 44
Page 17 and 18: 6.1 Page 17 of 44
Page 19 and 20: 6.2 Recurrent Non-muscle Invasive T
Page 21: 6.52 Radiotherapy Radical RT Fit p
Page 25 and 26: References 1. Tolley DA, Parmar MK,
Page 27 and 28: 28. Madersbacher S, Hochreiter W, B
Page 29 and 30: Appendix 2 - Referral Form Referrin
Page 31 and 32: Non-urgent referral • Refer non-u
Page 33 and 34: ‘Unexplained’ as used in the re
Page 35 and 36: Appendix 3 - TNM Classification of
Page 37 and 38: Appendix 5 - TCC Algorithm: New Non
Page 39 and 40: Appendix 7 - TCC Algorithm: Muscle
Page 41 and 42: Appendix 9 - Radiology Guidelines M
Page 43 and 44: Specific Anatomic Region Applicatio

guidelines for the management of urological cancer - Merseyside ...

Create successful ePaper yourself

Delete template?

Save as template?